Variants in estrogen-related genes and risk of Parkinson's disease

Movement Disorders

Volumn 26, Issue 7, 2011, Pages 1234-1242

  Chung, Sun Ju ^a,b   Armasu, Sebastian M ^a   Biernacka, Joanna M ^a   Lesnick, Timothy G ^a   Rider, David N ^a   Cunningham, Julie M ^a   Maraganore, Demetrius M ^a,c  

^a MAYO CLINIC   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Common genetic variation; Estrogen; Genes; Parkinson's disease; PRDM2

Indexed keywords

AROMATASE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENOMIC DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYP19A1 GENE; ESR 1 GENE; ESR 2 GENE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRDM 2 GENE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AROMATASE; CASE-CONTROL STUDIES; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TRANSCRIPTION FACTORS;

EID: 79959371598     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23604     Document Type: Article

References (46)

1. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002; 55: 25-31.
2. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999; 52: 1214-1220.
3. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000; 55: 1358-1363.
4. Chan RS, Huey ED, Maecker HL, et al. Endocrine modulators of necrotic neuron death. Brain Pathol. 1996; 6: 481-491.
5. Regan RF, Guo Y. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res. 1997; 764: 133-140.
6. Singer CA, Rogers KL, Strickland TM, Dorsa DM. Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 1996; 212: 13-16.
7. Sribnick EA, Ray SK, Nowak MW, et al. 17beta-estradiol attenuates glutamate-induced apoptosis and preserves electrophysiologic function in primary cortical neurons. J Neurosci Res. 2004; 76: 688-696.
8. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann N Y Acad Sci. 1998; 844: 153-165.
9. Bains M, Cousins JC, Roberts JL. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol. 2007; 204: 767-776.
10. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997; 767: 340-344.
11. Datla KP, Murray HE, Pillai AV, et al. Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle. Neuroreport. 2003; 14: 47-50.
12. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience. 2001; 103: 385-394.
13. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm. 2003; 110: 1215-1224.
14. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol. 1996; 18: 603-606.
15. Dluzen DE, McDermott JL, Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 1996; 66: 658-666.
16. Leranth C, Roth RH, Elsworth JD, et al. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci. 2000; 20: 8604-8609.
17. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord. 2001; 16: 830-837.
18. Saunders-Pullman R, Gordon-Elliott J, Parides M, et al. The effect of estrogen replacement on early Parkinson's disease. Neurology. 1999; 52: 1417.
19. Currie LJ, Harrison MB, Trugman JM, et al. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004; 61: 886-888.
20. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008; 70: 200-209.
21. Weel AE, Uitterlinden AG, Westendorp IC, et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab. 1999; 84: 3146-3150.
22. Maraganore DM, Farrer MJ, McDonnell SK, et al. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Mov Disord. 2002; 17: 509-512.
23. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005; 77: 685-693.
24. Maraganore DM. Blood is thicker than water: the strengths of family-based case-control studies. Neurology. 2005; 64: 408-409.
25. Rocca WA, Maraganore DM, McDonnell SK, Schaid DJ. Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol. 1998; 51: 517-523.
26. Hartge P, Brinton LA, Rosenthal JF, et al. Random digit dialing in selecting a population-based control group. Am J Epidemiol. 1984; 120: 825-833.
27. Potthoff RF. Telephone sampling in epidemiologic research: to reap the benefits, avoid the pitfalls. Am J Epidemiol. 1994; 139: 967-978.
28. Brighina L, Frigerio R, Schneider NK, et al. {Alpha>-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology. 2008; 70: 1461-1469.
29. Brighina L, Schneider NK, Lesnick TG, et al. Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study. Parkinsonism Relat Disord. 2009 15: 430-434.
30. Wise PM, Dubal DB, Wilson ME, et al. Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol. 2001; 22: 33-66.
31. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 437: 1299-1320.
32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21: 263-265.
33. Breslow NE, Day NE. Statistical methods in cancer research. Volume I-The analysis of case-control studies. IARC Sci Publ. 1980: 5-338.
34. Cox DR. Regression models of life-tables (with discussion). J R Stat Soc (Ser B). 1972; 34: 187-220.
35. Welch WJ, Gutierrez LG. Robust permutation tests for matched-pairs designs. J Am Stat Assoc. 1988; 83: 450-455.
36. Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 2006; 5: 911-916.
37. Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009; 124: 593-605.
38. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009; 41: 1308-1312.
39. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009; 41: 1303-1307.
40. Latourelle JC, Pankratz N, Dumitriu A, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009; 10: 98.
41. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord. 2000; 15: 819-825.
42. Rocca WA, Peterson BJ, McDonnell SK, et al. The Mayo Clinic Family Study of Parkinson's Disease: study design, instruments, and sample characteristics. Neuroepidemiology. 2005; 24: 151-167.
43. Kahvejian A, Quackenbush J, Thompson JF. What would you do if you could sequence everything? Nat Biotechnol. 2008; 26: 1125-1133.
44. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008; 24: 133-141.
45. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA. 2006; 296: 661-670.
46. Evangelou E, Maraganore DM, Annesi G, et al. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B: 220-228.